01 Liquid Biopsy NGS Is Expanding Blood-Based Cancer Profiling The clinical oncology next-generation sequencing market trends show that liquid biopsy NGS is shifting cancer profiling toward less-invasive blood-based testing using circulating cell-free DNA. This transition is expanding molecular profiling when tissue samples are difficult to obtain, with FDA-approved Guardant 360 Liquid CDx using plasma cfDNA to analyze 741 genes for multiple genomic alterations. The outcome is broader use of blood-based NGS for treatment selection and tumor profiling.
02 RNA Sequencing Is Expanding Detection of Clinically Relevant Gene Fusions RNA sequencing is expanding NGS beyond DNA mutations toward the detection of gene fusions and splice variants. This transition is strengthening the identification of clinically relevant alterations, with FDA-authorized TruSight Oncology Comprehensive detecting fusions in 24 genes and splice variants in one gene from RNA. The outcome is more comprehensive molecular profiling for targeted treatment decisions in solid tumors.
01 Broader Use of Companion Diagnostics and Availability of Targeted Cancer Therapies Drive Market Companion diagnostics are increasingly used to identify patients whose tumors contain biomarkers linked to specific targeted treatments. NGS-based testing can evaluate multiple genomic biomarkers in a single workflow, allowing clinicians to select appropriate therapies without requiring separate tests for each alteration. This clinical connection between biomarker identification and treatment selection creates recurring demand for NGS-based diagnostic testing.The expanding availability of targeted cancer therapies strengthens this demand by increasing the need for molecular characterization before treatment decisions. NGS enables broader genomic assessment from limited tumor samples, helping identify alterations that may guide therapy selection across different cancer types. As more targeted treatments enter clinical practice, the need for reliable genomic testing supports continued adoption of NGS platforms and clinical sequencing services.
01 Complex Data Interpretation and Limited Tissue Sample Quality Restrain Clinical Oncology Next-Generation Sequencing Market Expansion Complex genomic datasets generated through NGS require specialized bioinformatics expertise and clinical interpretation to identify actionable alterations accurately. Limited availability of trained professionals and interpretation complexity can increase workflow requirements, delay reporting, and slow the integration of NGS into routine oncology care.Limited availability of high-quality tissue samples can reduce the reliability of sequencing results when samples contain insufficient tumor material or degraded DNA. Additional sample collection or repeat biopsies can increase clinical burden and delay genomic testing, restricting the wider adoption of NGS in oncology.
01 NGS-Based Tumor Profiling for Rare Cancers and Tumor-Normal Sequencing Create New Market Opportunities Molecular diagnostic companies, oncology laboratories, and sequencing providers can develop specialized NGS panels for rare cancers where diverse genomic profiles require focused testing solutions. Companies such as Foundation Medicine and Tempus can generate revenue through disease-specific panels, sequencing services, and clinical interpretation while supporting clinical oncology next-generation sequencing market growth.Oncology laboratories, genomic testing companies, and sequencing providers can expand tumor-normal sequencing workflows that compare tumor DNA with matched normal DNA to distinguish acquired alterations from inherited variants. Companies such as Illumina and QIAGEN can generate revenue through sequencing platforms, sample-preparation products, and bioinformatics solutions, creating additional commercial opportunities.
01 Inconsistent Clinical Adoption and Fragmented Genomic Knowledge Hinder Market Growth Inconsistent clinical adoption across healthcare settings creates uneven demand for NGS testing, as hospitals and oncology practices differ in testing workflows, institutional policies, and access to genomic services. This variation can slow broader integration of NGS into routine cancer care and make market expansion across healthcare systems more difficult. In 2025, a community-oncology study identified differences in testing practices and organizational barriers affecting NGS implementation.Fragmented genomic knowledge bases can make it difficult for laboratories and clinicians to consistently interpret and apply rapidly expanding genomic evidence. Differences in databases, annotation methods, and evidence classifications can complicate the use of NGS findings across clinical settings and increase the effort required to maintain reliable genomic resources. Thus, fragmented genomic knowledge bases become a major issue among key players.
July 2026 CareDx completed the acquisition of Naveris, expanding its precision oncology portfolio with the NavDx® molecular residual disease test for HPV-related cancers. The acquisition strengthens its oncology diagnostics and NGS-based testing capabilities.
June 2026 Illumina launched an enhanced clinical oncology sequencing workflow with improved automation and faster turnaround, enabling more efficient genomic profiling for precision cancer diagnostics.
April 2026 Thermo Fisher Scientific expanded its Oncomine™ portfolio with new NGS-based assays for comprehensive tumor profiling, supporting precision oncology and targeted therapy selection.
February 2026 QIAGEN introduced an advanced oncology workflow integrating NGS library preparation with bioinformatics solutions to improve clinical cancer testing efficiency and reporting accuracy.